Trial Profile
A phase 2 study of Veyondain sarcomas/rare cancers
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- Acronyms DARRT-3
- 29 Oct 2018 New trial record
- 22 Oct 2018 According to a Noxopharm media release, the company is planning to initiate this DARRT-3 study in rare cancer in Q2 2019.